INDIE Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (Aktiv)
Zweitlinie oder später
AERN Abskopaler Effekt von Radiotherapie und Nivolumab bei anti-PD1 vorbehandeltem rezidiviertem oder refraktärem Hodgkin-Lymphom (HL) (Aktiv)
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
HD 21 Treatment optimization Trial in the first-line Treatment of advanced stage Hodgin-Lymphoma (Aktiv)
MK7684A-004 Phase II Studie zu MK-7684A (Vibostolimab/Pembrolizumab) bei rezidivierenden/refraktären hämatologischen Krebserkrankungen (Aktiv)